Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms

Launched by SOHAG UNIVERSITY · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to find a reliable and affordable way to tell the difference between two common conditions that affect the gut: Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Many people experience ongoing issues like diarrhea, abdominal pain, or changes in their bowel habits, and it can be challenging to know what is causing these symptoms. By identifying a specific biomarker—a biological marker in the body—this study aims to reduce the need for more invasive tests that can be uncomfortable for patients.

To be eligible for the trial, participants need to be adults (18 years and older) who have been experiencing these gastrointestinal symptoms for more than six weeks and do not already have a diagnosis of IBS or IBD. They should also not have used certain medications recently that could interfere with the study results. If you decide to participate, you’ll be helping researchers find better ways to diagnose these conditions, which could ultimately lead to better care for many others in the future. The trial is not yet recruiting participants, but it’s an important step toward improving how we understand and treat gut health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.
• • Patients with no prior diagnosis of IBD or IBS.
• • Patients willing to provide informed consent and comply with study requirements.
• • Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels
• Exclusion Criteria:
• • Patients with a confirmed diagnosis of IBD and currently on treatment.
• • Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.
• • Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.
• • Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.
• • Pregnant or lactating women.